To synthesize available evidence on dual targeted therapy (DTT) for hidradenitis suppurativa (HS) and contextualize findings with data from other immune-mediated diseases, highlighting its potential significance in HS management.
Key Findings:
DTT has shown clinical improvement in HS patients with limited treatment options, suggesting a need for further exploration of its implications in clinical practice.
Interpretation:
DTT may enhance treatment efficacy for recalcitrant HS by targeting multiple inflammatory pathways, although further research is needed to confirm safety and efficacy, particularly in specific patient populations.
Limitations:
Current evidence is limited to sparse case reports without controlled trials, which may affect the reliability of the findings and their applicability to broader patient populations.
Conclusion:
DTT represents a promising strategy for managing severe HS, warranting further prospective evaluation to address the limitations and enhance treatment options.
by Kenan Kherallah, Claire S. Chung, Raveena Ghanshani, Alexandra Charrow, Julia M. Riley, Christopher J. Sayed, Vivian Y. Shi, Katrina H. Lee, Jennifer L. Hsiao
